$1.49 Billion is the total value of Rock Springs Capital Management LP's 133 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| WCG | WELLCARE HEALTH PLANS INC | $32,145,000 | +17.1% | 234,500 | 0.0% | 2.15% | +25.0% | |
| ONCE | SPARK THERAPEUTICS INC | $31,188,000 | -16.9% | 625,000 | 0.0% | 2.09% | -11.3% | |
| AAAP | ADVANCED ACCELERATOR APPLICsponsored ads | $24,887,000 | -29.7% | 930,000 | 0.0% | 1.66% | -25.0% | |
| TBPH | THERAVANCE BIOPHARMA INC | $19,128,000 | -12.0% | 600,000 | 0.0% | 1.28% | -6.1% | |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15,867,000 | -23.6% | 410,000 | 0.0% | 1.06% | -18.4% | |
| GLPG | GALAPAGOS NVspon adr | $13,480,000 | -0.7% | 210,000 | 0.0% | 0.90% | +6.0% | |
| WBA | WALGREENS BOOTS ALLIANCE INC | $13,324,000 | +2.7% | 161,000 | 0.0% | 0.89% | +9.6% | |
| DHR | DANAHER CORP DEL | $12,454,000 | -0.7% | 160,000 | 0.0% | 0.83% | +6.0% | |
| PTHN | PATHEON N V | $11,484,000 | -3.1% | 400,000 | 0.0% | 0.77% | +3.4% | |
| HLS | HEALTHSOUTH CORP | $10,929,000 | +1.7% | 265,000 | 0.0% | 0.73% | +8.5% | |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10,355,000 | -10.5% | 125,000 | 0.0% | 0.69% | -4.4% | |
| RTRX | RETROPHIN INC | $9,881,000 | -15.4% | 522,000 | 0.0% | 0.66% | -9.7% | |
| BOLD | AUDENTES THERAPEUTICS INC | $8,861,000 | +2.6% | 485,000 | 0.0% | 0.59% | +9.6% | |
| EGALET CORPnote 5.500% 4/0 | $6,791,000 | +1.6% | 7,800,000 | 0.0% | 0.45% | +8.4% | ||
| AVXS | AVEXIS INC | $6,682,000 | +15.8% | 140,000 | 0.0% | 0.45% | +23.5% | |
| VRTX | VERTEX PHARMACEUTICALS INC | $6,612,000 | -15.5% | 89,750 | 0.0% | 0.44% | -10.0% | |
| CRVS | CORVUS PHARMACEUTICALS INC | $6,435,000 | -13.1% | 450,000 | 0.0% | 0.43% | -7.1% | |
| RTIX | RTI SURGICAL INC | $6,045,000 | +3.8% | 1,860,000 | 0.0% | 0.40% | +11.0% | |
| AIMT | AIMMUNE THERAPEUTICS INC | $5,992,000 | +36.3% | 293,000 | 0.0% | 0.40% | +45.3% | |
| PTI | PROTEOSTASIS THERAPEUTICS IN | $5,517,000 | -21.4% | 450,000 | 0.0% | 0.37% | -16.1% | |
| CO | CHINA CORD BLOOD CORP | $5,386,000 | +19.8% | 880,000 | 0.0% | 0.36% | +27.7% | |
| MEDP | MEDPACE HLDGS INC | $4,869,000 | +20.8% | 135,000 | 0.0% | 0.33% | +28.9% | |
| ADRO | ADURO BIOTECH INC | $4,731,000 | -8.3% | 415,000 | 0.0% | 0.32% | -1.9% | |
| ASMB | ASSEMBLY BIOSCIENCES INC | $4,739,000 | +68.5% | 390,000 | 0.0% | 0.32% | +80.1% | |
| MGNX | MACROGENICS INC | $4,599,000 | -31.7% | 225,000 | 0.0% | 0.31% | -27.0% | |
| CGEN | COMPUGEN LTDord | $4,208,000 | -19.0% | 825,000 | 0.0% | 0.28% | -13.5% | |
| XENT | INTERSECT ENT INC | $4,175,000 | -23.6% | 345,000 | 0.0% | 0.28% | -18.7% | |
| NVDQ | NOVADAQ TECHNOLOGIES INC | $3,935,000 | -38.7% | 555,000 | 0.0% | 0.26% | -34.7% | |
| AGNPRA | ALLERGAN PLCpfd conv ser a | $3,820,000 | -7.0% | 5,000 | 0.0% | 0.26% | -0.4% | |
| ALDR | ALDER BIOPHARMACEUTICALS INC | $3,786,000 | -36.5% | 182,000 | 0.0% | 0.25% | -32.4% | |
| JUNO | JUNO THERAPEUTICS INC | $3,713,000 | -37.2% | 197,001 | 0.0% | 0.25% | -33.2% | |
| MEDICINES COnote 2.500% 1/1 | $3,611,000 | -7.4% | 3,000,000 | 0.0% | 0.24% | -0.8% | ||
| INVA | INNOVIVA INC | $3,605,000 | -2.6% | 336,900 | 0.0% | 0.24% | +3.9% | |
| KITE | KITE PHARMA INC | $3,542,000 | -19.7% | 79,000 | 0.0% | 0.24% | -14.4% | |
| OTIC | OTONOMY INC | $3,339,000 | -12.6% | 210,000 | 0.0% | 0.22% | -6.7% | |
| CRME | CARDIOME PHARMA CORP | $3,312,000 | -11.7% | 1,200,000 | 0.0% | 0.22% | -5.5% | |
| ITCI | INTRA CELLULAR THERAPIES INC | $2,867,000 | -1.0% | 190,000 | 0.0% | 0.19% | +5.5% | |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $2,734,000 | -42.6% | 675,000 | 0.0% | 0.18% | -38.6% | |
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $2,564,000 | -3.3% | 73,000 | 0.0% | 0.17% | +3.6% | |
| EGLTQ | EGALET CORP | $2,295,000 | +0.5% | 300,000 | 0.0% | 0.15% | +7.7% | |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $2,280,000 | -32.1% | 524,089 | 0.0% | 0.15% | -27.5% | |
| MCRB | SERES THERAPEUTICS INC | $2,178,000 | -19.5% | 220,000 | 0.0% | 0.15% | -14.1% | |
| GNCA | GENOCEA BIOSCIENCES INC | $1,978,000 | -19.5% | 480,000 | 0.0% | 0.13% | -14.3% | |
| NVCR | NOVOCURE LTD | $1,682,000 | -8.1% | 214,316 | 0.0% | 0.11% | -1.7% | |
| TNDM | TANDEM DIABETES CARE INC | $1,279,000 | -71.9% | 595,000 | 0.0% | 0.09% | -69.9% | |
| DMTX | DIMENSION THERAPEUTICS INC | $1,180,000 | -45.6% | 271,370 | 0.0% | 0.08% | -41.9% | |
| NVLS | NIVALIS THERAPEUTICS INC | $1,095,000 | -72.5% | 489,000 | 0.0% | 0.07% | -70.7% | |
| WRIGHT MED GROUP INCnote 2.000% 2/1 | $1,047,000 | -2.4% | 1,000,000 | 0.0% | 0.07% | +4.5% | ||
| CHMA | CHIASMA INC | $960,000 | -33.7% | 492,500 | 0.0% | 0.06% | -29.7% | |
| DVAX | DYNAVAX TECHNOLOGIES CORP | $652,000 | -62.3% | 165,000 | 0.0% | 0.04% | -59.6% | |
| CERU | CERULEAN PHARMA INC | $443,000 | -32.3% | 625,000 | 0.0% | 0.03% | -26.8% | |
| INFI | INFINITY PHARMACEUTICALS INC | $365,000 | -13.3% | 270,000 | 0.0% | 0.02% | -7.7% | |
| OREXQ | OREXIGEN THERAPEUTICS INC | $288,000 | -47.5% | 165,300 | 0.0% | 0.02% | -44.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.